Legal Status Overview
Gray AreaPeptides in New York occupy a legal gray area because no New York statute, administrative code, or Board of Pharmacy rule names 'peptides' or 'research chemicals' as a distinct regulated category. Instead, New York relies on its general Education Law/Public Health Law pharmacy-practice and compounding framework layered on top of federal FDA drug law, meaning a peptide's legality turns on its individual FDA approval and bulk-drug-substance status rather than on any New York-specific peptide rule. FDA-approved peptide medicines are lawful only as prescription drugs dispensed through New York-licensed pharmacies, while unapproved research peptides are neither expressly legalized nor specifically criminalized under New York law, but their sale for human use is restricted by the same federal misbranding/unapproved-drug rules the FDA enforces nationwide.
Key Points
- New York has no statute, regulation, or Board of Pharmacy rule that names 'peptides,' 'research chemicals,' or research-use-only compounds as a distinct legal category, according to a review of New York statutes and NYSED pharmacy regulations. [1]
- New York's Commissioner of Education regulations at Part 63 set the physical, storage, and sterile-compounding conditions that registered New York pharmacies must meet, and these general compounding rules -- not any peptide-specific rule -- govern compounded injectable peptides in the state. [1]
- New York has added a one-hour compounding continuing-education credit requirement for licensed pharmacists as part of a broader wave of state-level regulatory activity responding to compounded semaglutide and other compounded drugs. [2]
- The FDA classifies BPC-157 as a substance with safety concerns, which as of the Holt Law analysis placed it on the Category 2 bulk drug substances list and prohibited licensed 503A/503B compounding pharmacies -- including those in New York -- from compounding it for human use. [3]
- The FDA's Pharmacy Compounding Advisory Committee met in July 2026 and voted by a narrow 8-6 margin to recommend moving BPC-157 to Category 1, but only in connection with a proposed ulcerative colitis indication rather than a blanket approval for general compounding. [4]
- New York schedules anabolic steroids as a controlled substance under subdivision (h) of Schedule II of Public Health Law Section 3306, but research peptides such as BPC-157 and TB-500 are not listed on that state controlled-substance schedule. [1]
- New York General Business Law Section 391-oo, effective April 22, 2024, bars retail sale of over-the-counter weight-loss or muscle-building dietary supplements to anyone under 18, but this consumer-protection provision targets marketing claims rather than peptides specifically. [1]
- No New York-specific rule was found governing personal importation or travel with peptides for individual use; because research peptides are not scheduled as controlled substances in New York, possession for personal use is not independently criminalized under state law, though selling or distributing unapproved peptide products for human consumption remains restricted by the federal unapproved-drug framework the FDA applies nationwide. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in New York
| BPC-157 | BPC-157 is not FDA-approved and, per FDA's bulk drug substance classification analyzed by compounding-law commentators, was designated a 'Substance with Safety Concerns' that licensed compounding pharmacies -- including any in New York -- were prohibited from compounding for human use, a restriction only narrowly and partially reconsidered by an FDA advisory committee in July 2026. [3] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Brand-name semaglutide and tirzepatide products are legal in New York only as FDA-approved prescription medicines dispensed through licensed pharmacies, while compounded or 'research-grade' versions face a sharply narrowed legal basis now that the FDA has resolved the national shortages that previously permitted broader compounding, driving a wave of state-level enforcement scrutiny around the country. [8] |
| TB-500 | TB-500 is sold in New York as an unapproved 'research use only' peptide that is not carved out by any New York-specific law and, like other unapproved research peptides, falls under the same federal misbranding/unapproved-drug framework the FDA enforces rather than any distinct New York rule. [1] |
| Human Growth Hormone (HGH/somatropin) | No New York-specific statute or Board of Pharmacy rule addressing HGH/somatropin peptides was identified in this research, so its status in New York cannot be confirmed beyond the general inference that FDA-approved somatropin products require a prescription while unapproved HGH-related peptides fall under general federal drug law. |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides in New York without a prescription?
No -- in New York, FDA-approved peptide drugs (such as insulin analogs or GLP-1 medicines) can only be lawfully sold with a valid prescription dispensed through a licensed pharmacy, and unapproved 'research use only' peptides like BPC-157 cannot be lawfully sold for human consumption at all under the federal unapproved-drug framework that applies in New York as elsewhere. [1]
Is BPC-157 legal in New York?
BPC-157 is in a legal gray area in New York: it is not a controlled substance under New York law, but it is also not FDA-approved, and FDA's classification of it as a substance with safety concerns has meant licensed compounding pharmacies could not compound it for human use, a restriction that only began to loosen slightly after a narrow 2026 FDA advisory committee vote tied to one specific indication. [3]
Can a New York telehealth provider legally prescribe compounded semaglutide or tirzepatide?
The legal basis for routine compounded semaglutide and tirzepatide prescribing has narrowed sharply now that the FDA has resolved the national drug shortages that previously justified broad compounding, meaning New York prescribers and pharmacies are subject to increasing federal and state scrutiny of compounded GLP-1 products, though no New York-specific telehealth statute naming peptides was identified in this research. [8]
What are the penalties for selling research peptides in New York?
No New York-specific statute was found that creates penalties unique to peptide sales; instead, sellers of unapproved research peptides for human use in New York remain exposed to federal FDA enforcement (warning letters, misbranding and unapproved-drug actions) and to New York's general pharmacy-practice and consumer-protection laws rather than any peptide-specific penalty provision.
Does New York require a special license to compound peptides like BPC-157?
New York does not have a peptide-specific compounding license; instead, pharmacies compounding any injectable product, including peptides, must meet New York's general sterile-compounding standards under Commissioner of Education regulations Part 63, and separately must comply with whatever federal Category 1/Category 2 bulk-drug-substance status the FDA has assigned to that specific peptide. [1]